Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB)

Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is the leading cause of death from an infectious disease globally. The wide-spread and ever-increasing resistance to TB drugs is reducing the effectiveness of treatment and jeopardizing TB control. New effective drugs with acceptable safety profiles are needed to turn the tide. Since the early 1990s, Otsuka Pharmaceutical Co., Ltd. has had a TB drug development program that resulted in the selection and development of delamanid (OPC-67683, Deltyba ®), a first-in-class bicyclic nitroimidazole.

Source: Tuberculosis - May 3, 2018 Category: Respiratory Medicine Authors: Yongge Liu, Makoto Matsumoto, Hidekaza Ishida, Kinue Ohguro, Masuhiro Yoshitake, Rajesh Gupta, Lawrence Geiter, Jeffrey Hafkin Tags: Review Source Type: research